Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole

Drug Metabolism and Disposition

Volumn 31, Issue 5, 2003, Pages 540-547

  Hyland, Ruth ^a   Jones, B C ^a   Smith, D A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FURAFYLLINE; KETOCONAZOLE; QUINIDINE; SULFAPHENAZOLE; UK 121265; UNCLASSIFIED DRUG; VORICONAZOLE;

CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SUBSTRATE; GENOTYPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; INHIBITION KINETICS; LIVER MICROSOME; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC N-OXIDES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; MICROSOMES, LIVER; OXIDATION-REDUCTION; PYRIMIDINES; QUINIDINE; SULFAPHENAZOLE; THEOPHYLLINE; TRIAZOLES;

EID: 0037403687     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.5.540     Document Type: Conference Paper

References (24)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of CYP3A and 2C9. Xenobiotica 25:261-270.
2. Chandrasekar PH and Manavathu E (2001) Voriconazole: a second-generation triazole. Drugs Today 37:135-148.
3. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, and Monzon A (1998) Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 42:531-533.
4. DeWaziers I, Cugnenc PH, Yang CS, Leroux J-P, and Beaune PH (1990) Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394.
5. Doeke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN, and McManus ME (1991) Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 31:125-130.
6. Espinel-Ingroff A (1998) In vitro activity of the new triazole voriconazole (UK-109496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 36:198-202.
7. European Public Assessment Report (EPAR) for Vfend (2002) Summary of product characteristics, Published by the EMEA, April 3, 2002. www.emea.eu.int.
8. Funae Y and Imaoka S (1987) Purification and characterisation of liver microsomal cytochrome P450 from untreated male rats. Biochim Biophys Acta 926:349-358.
9. Hyland R, Roe EGH, Jones BC, and Smith DA (2001) Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 51:239-248.
10. Koltin Y and Hitchcock CA (1997) Progress in the search for new triazole antifungal agents. Curr Opin Chem Biol 1:176-182.
11. Kronbach T, Mathys D, Gut J, Catin T, and Meyer UA (1987) High performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32.
12. Kubota T, Chiba K, and Ishizaki T (1996) Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60:661-666.
13. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
14. Maurice M, Emiliani S, Dalet-Beluche I, Derancourt J, and Lange R (1991) Isolation and characterisation of the IIa subfamily from human liver microsomes. Ear J Biochem 200:511-517.
15. Meier UT, Kronbach T, and Meyer UA (1985) Assay for mephenytoin metabolism in human liver microsomes by high performance liquid chromatography. Anal Biochem 151:286-291.
16. Newton DJ, Wang RW, and Lu AYH (1995) Cytochrome P450 inhibitors, evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
17. Omuro T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. 1. Evidence for its hemoprotein nature, J Biol Chem 239:2370-2378.
18. Perfect J, Gonzalez-Ruiz A, and Lutsar I (2000) Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens, Abstract 303 in Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America; Sept. 7-10, 2000; New Orleans. LA. Infectious Diseases Society of America, Alexandria, VA.
19. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, and Kleinermans D (2002) Pharmacokinetic and safety of voriconazole following intravenous to oral dose escalation regimens. Antimicrob Agents Chemother 46:2546-2553.
20. Sheehan DJ, Hitchcock CA, and Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40-79.
21. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
22. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ, and Miners JO (1993) Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 46:1975-1981.
23. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, and Lutsar I (2000) Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection, Abstract 305 in Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America; Sept. 7-10, 2000; New Orleans, LA. Infectious Diseases Society of America. Alexandria, VA.
24. Xie H-G, Stein CM, and Kim RB (1999) Allelic genotyping and phenotyping distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9:539-549.